Abstract
Czerwinska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A. Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives. Molecules. 2020;25. https://doi.org/10.3390/molecules25071743. Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721–8. https://doi.org/10.1007/s00259-019-04612-0. CAS Article Google Scholar Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62–9. https://doi.org/10.2967/jnumed.119.229229. CAS Article Google Scholar Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. (225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38. https://doi.org/10.1007/s00259-018-4167-0. CAS Article PubMed Google Scholar Download references Open Access funding enabled and organized by Projekt DEAL. Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany Harun Ilhan, Astrid Gosewisch, Guido Boning, Friederike Volter, Mathias Zacherl, Peter Bartenstein, Andrei Todica & Franz Josef Gildehaus Department of Radiology, University Hospital, LMU Munich, Munich, Germany Marcus Unterrainer You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar Correspondence to Harun Ilhan. All procedures performed in this study involving human participants were in accordance with ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective evaluation was approved by the local ethic committee (20-178). Written informed consent was obtained prior to the exam. The authors declare that they have no conflict of interest. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This article is part of the Topical Collection on Image of the month. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and Permissions Ilhan, H., Gosewisch, A., Boning, G. et al. Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC. Eur J Nucl Med Mol Imaging (2020). https://doi.org/10.1007/s00259-020-05023-2 Download citation Received: 13 June 2020 Accepted: 31 August 2020 Published: 22 September 2020 DOI: https://doi.org/10.1007/s00259-020-05023-2
Highlights
PSA values are provided under the date of each PSMAPET MIP image (A–B using 68Ga-PSMA-11 and E–H using 18F-PSMA-1007)
The patient was referred for RLT after radical prostatectomy and radiotherapy in
PSA was still decreasing after two additional 177Lu-PSMA-617 cycles despite increasing PSMA-ligand uptake in PSMAPET (C)
Summary
Remains challenging as RLT already represents last-line treatment. The α-emitter 225Ac provides higher biological effectiveness compared with 177Lu [1]. PSA values are provided under the date of each PSMAPET MIP image (A–B using 68Ga-PSMA-11 and E–H using 18F-PSMA-1007). 2005, and anti-hormonal therapy started in 2013 due to biochemical progression. Further progression was observed in February 2017 (A) after 2nd-line anti-hormonal therapy from 2015 to 2016, 223Ra-Dichloride in 2016, and docetaxel chemotherapy from 2016 to 2017.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.